Displaying 13 - 24 of 32
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unfolding the metabolic dysfunction of MASH: exploring the pathophysiology and outcomes - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unfolding the metabolic dysfunction of MASH: exploring the pathophysiology and outcomes - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unfolding the metabolic dysfunction of MASH: exploring the pathophysiology and outcomes - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Cirrhosis & Complications
1

Sobi: When Platelet Count Matters: Prophylaxis Ahead of Procedures in Chronic Liver Disease Patients (CLD) - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View
Displaying 13 - 24 of 32